文献速递甲状腺疾病骨质疏松与钙磷/甲状旁腺

甲状腺髓样癌骨转移:与溶骨性形态相关的高发病率与不良预后

Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

这项回顾性队列研究在4家德国转诊中心纳入1060例甲状腺髓样癌(MTC)患者,其中416例转移性MTC中120例(29%)存在骨转移,97%合并非骨转移。骨转移中溶骨性形态占32%,溶骨性转移与总生存受损相关(HR 3.85,95%CI 1.52-9.77,P=.005),接受抗骨吸收治疗(ART)的36例患者骨相关事件(SREs)显著少于未治疗者(P=.04)。

要点

  • 416例转移性MTC中120例(29%)有骨转移,97%合并非骨转移。
  • 溶骨性转移与总生存受损相关(HR 3.85,95%CI 1.52-9.77,P=.005)。
  • 36例接受ART者SREs显著少于未治疗者(P=.04)。

核心结论

  • 骨转移在转移性MTC中常见,多为溶骨性形态且预后不良,多数SREs发生于溶骨性转移,可能通过ART预防。

研究设计与样本

  • 回顾性队列研究,在4家德国转诊中心纳入1060例MTC患者。

主要发现

  • 416例转移性MTC中120例(29%)有骨转移,其中97%合并非骨转移。
  • 骨转移发生于初诊后中位2.1年(范围-0.1至20.6年),79%为多灶性,86%位于脊柱,60%位于骨盆。
  • 骨转移形态为溶骨性32%、成骨性25%、混合性22%(未知21%)。
  • 骨转移诊断后中位观察26.6个月(范围0-188个月)内,47%患者发生至少一次SREs(骨放疗50%,病理性骨折32%),42%发生于溶骨性转移、17%发生于成骨性转移(P=.047)。
  • 溶骨性转移与总生存受损相关(HR 3.85,95%CI 1.52-9.77,P=.005),SREs发生与总生存受损无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The clinical relevance of bone metastases (BM) in advanced medullary thyroid carcinoma (MTC) is poorly described. OBJECTIVE: The objectives of this work are to describe the prevalence of BM, frequency of skeletal related events (SREs), and impact of BM morphology and SREs on prognosis, and to assess the role of antiresorptive treatment (ART). DESIGN: A retrospective cohort study was conducted. SETTING: This study was conducted at 4 German referral centers. PATIENTS: A total of 1060 MTC patients were included. MAIN OUTCOME MEASURE: Main outcome measures include descriptive statistics, overall survival (OS) by the Kaplan-Meier method, and risk factors by Cox proportional hazards modeling. RESULTS: A total of 120 of 416 patients (29%) with metastatic MTC had BM, of which 97% had concurrent nonosseous metastases. BM occurred 2.1 years (median, range -0.1 to 20.6 years) after initial diagnosis, were multifocal in 79%, and were located preferentially in the spine (86%) and pelvis (60%). BM morphology was osteolytic in 32%, osteoblastic in 25%, and mixed in 22% of cases (unknown: 21%). Within a median observation period of 26.6 months (range, 0-188 months) after BM diagnosis, 47% of patients experienced one or more SREs (bone radiation 50%, pathological fractures 32%), of which 42% occurred in osteolytic and 17% in osteoblastic BM (P = .047). Presence of osteolytic metastases (hazard ratio 3.85, 95% CI 1.52-9.77, P = .005) but not occurrence of SREs was associated with impaired OS. Among the 36 patients who received ART (no ART: n = 71), SREs were significantly less frequent than in untreated patients (P = .04). CONCLUSION: BM are common in metastatic MTC and most often with an osteolytic morphology and an unfavorable prognosis. The majority of SREs occur in osteolytic metastases and may be prevented by ART.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Vogel T, Wendler J, Frank-Raue K, et al. Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. J Clin Endocrinol Metab. 2020. PMID: 32072159. doi:10.1210/clinem/dgaa077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。